ロード中...
Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
AIM: Liraglutide, a once-daily subcutaneous glucagon-like peptide-1 (GLP-1) agonist, is approved for treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM). For patients with established cardiovascular diseases, liraglutide has also been shown to reduce major cardiovascular even...
保存先:
| 出版年: | Clinicoecon Outcomes Res |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6635895/ https://ncbi.nlm.nih.gov/pubmed/31372015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S201951 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|